×

Biotech and Pharmaceuticals Medicine

  • A flu shot being administered in Concord, California.

    This year's flu vaccine isn't quite as good as last year's formula, according to the CDC. NBC News reports.

  • SHANGHAI, Feb 17- Four years ago, a bird flu outbreak in China killed at least three dozen people, triggered mass poultry culling, put masks on millions of Chinese faces and hammered shares in fast food and travel companies. The number of posts mentioning "bird flu" or "H7N9" on China's popular Sina Weibo microblog- a useful proxy for gauging consumer interest or...

  • The drugmaker's shares were up 2.37 percent at 4,554 pence on the London Stock Exchange, while its U.S.-listed shares were up 1.70 percent at $29.25 in premarket trading on Friday. Lynparza, which won U.S. approval for ovarian cancer in 2014 and generated 2016 sales of $218 million, is one of the drugs that the drugmaker hopes will help achieve its target of more...

  • *With H7N9 strain, poultry show few symptoms. *Over 100 people have died from bird flu in China this winter. BEIJING, Feb 17- Bird flu infection rates on Chinese poultry farms may be far higher than previously thought, because the strain of the deadly virus that has killed more than 100 people this winter is hard to detect in chickens and geese, animal health experts say.

  • Chief Executive Flemming Ornskov said Shire had delivered record product sales and earnings in a year when it bought hemophilia drugs company Baxalta for $32 billion and launched a new medicine for dry eye disease. Total product sales would rise to $14.5- 14.8 billion this year, up from $10.9 billion, Shire said, and earnings per share would rise to $14.60- $15.20.

  • Soliris, approved for rare blood disorders paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, generated quarterly sales of $749 million, underwhelming consensus estimates of $756 million, according to Barclays. The New Haven, Connecticut- based company forecast 2017 adjusted earnings of $5.00- $5.25 per share and revenue of...

  • This scanning electron micrograph depicts a number of Leptospira sp. bacteria.

    The three cases occurred in the past two months in a Bronx neighborhood. City officials say it's the first time a cluster of cases has been identified.

  • Bioverative's hemophilia hopes

    CNBC's Meg Tirrell speaks with John Cox, Bioverativ CEO, about the company's spinoff from Biogen, its new innovations in treating hemophilia.

  • LONDON, Feb 15- Treatment with two important cancer drugs is about to get much cheaper in Europe with a cut-price copy of Roche's blood cancer drug Rituxan likely to hit the market imminently followed by a rival to its breast cancer medicine Herceptin. Approval from the pan-European regulator, the European Medicines Agency, is pending and preparations are...

  • Doctor and senior patient

    By 2030, 70 percent of HIV patients will be over 50. Now success of HIV drugs poses a new challenge: treating it as a geriatric condition.

  • LONDON, Feb 14- Gilead Sciences has thrown down a challenge to GlaxoSmithKline with good clinical trial results for an experimental HIV drug that works in the same way as the British group's successful dolutegravir. Gilead's bictegravir, another so-called integrase inhibitor drug, delivered 97 percent virus suppression, making it just as effective as GSK's...

  • BRIEF-GSK ANNOUNCES POSITIVE FINAL STAGE RESULTS FOR TWO-DRUG. *VIIV phase III results dolutegravir& rilpivirine. *Headline results were announced in December 2016.

  • Feb 10- Drug developer Immunomedics Inc said on Friday it entered into a development and licensing deal worth up to $2 billion for its experimental cancer drug with Seattle Genetics Inc.. The drug is currently in an early stage study in advanced breast cancer patients whose disease has progressed despite multiple therapies, and has won the U.S. Food and Drug...

  • dog veterinarian pet care

    Pet care is now very advanced, and expensive. But veterinary experts say you don’t have to spend a bundle to increase a pet's life span.

  • PBMs are able to negotiate on drug prices: Dave Dorman

    Dave Dorman, CVS Health non-excutive chairman and former AT&T chairman & CEO, discusses the issues around drug pricing and pharmaceutical companies.

  • Are cures bad for business?

    Discussing the potential downside to pharmaceutical companies developing cures with Dr. Peter Bach, Memorial Sloan Kettering Center for Health Policy, and Brian Skorney, Baird biotechnology analyst. CNBC's Meg Tirrell also weighs in.

  • Gilead's catch-22 on Hep C cure

    CNBC's Meg Tirrell reports on Gilead's new drug that cures Hepatitis C.

  • MONTREAL _ Theratechnologies Inc. on Wednesday reported fiscal fourth-quarter net income of $129,000. The Montreal- based company said it had net income of less than 1 cent on a per-share basis. This story was generated by Automated Insights using data from Zacks Investment Research.

  • FRANKFURT, Feb 8- Bayer's best-selling blood-thinning drug Xarelto has also proved effective in preventing heart attacks and strokes in patients suffering from certain types of artery disease, the company said on Wednesday. The company, which is buying seeds maker Monsanto, raised its annual peak sales potential estimate for the drug last year to more than 5...

  • Feb 8- U.S. biopharmaceutical company Tesaro Inc is discussing its options with investment banks after receiving acquisition interest from several drugmakers, according to people familiar with the matter. Tesaro shares rose as much as 17 percent on the news and were up 11 percent at $180.50 in late morning trading in New York on Wednesday, giving the company a...